





PHARMACEUTICAL 2023

Avalo Therapeutics Inc.
Rank 380 of 446



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 155% points.

The company's Economic Capital Ratio, given in the ranking table, is -156%, being 199% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,416
Cost of Goods Sold	3,434
Intangible Assets	14,409
Liabilities, Current	22,114
Liabilities, Non-Current	1,711
Other Assets	2,542
Other Compr. Net Income	0
Other Expenses	66
Other Liabilities	20,457
Other Net Income	-4,190
Other Revenues	18,051
Property and Equipment	0
Research and Development	31,308
Selling, General and Administrative Expense	20,711

Output Variable	Value in 1000 USD
Assets	33,367
Liabilities	44,282
Expenses	55,519
Revenues	18,051
Stockholders Equity	-10,915
Net Income	-41,658
Comprehensive Net Income	-41,658
Economic Capital Ratio	-156%